Background. Necrotizing skin and soft tissue infections (NSTI) are rare but potentially life-36
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Postoperatively, patients with septic shock should be admitted to a critical care area. A proposed 251 algorithm for the management of patients with suspected NSTI is given in Figure 4 . 252
253

Patient transfer 254
Given the incidence of NSTI many physicians and surgeons may only rarely encounter NSTI. 255
Experience in diagnosing and treating patients (particularly the surgical debridement) may 256 therefore be limited and a transfer to a specialized center may be considered. In a study from 257
France [22] , the volume of patients treated was linked to improved outcomes. The decision to 258 transfer a patient to a specialized center should be based on the experience and availability of a 259 surgeon, the extent and severity of the skin lesions as well as the delay that would be incurred by 260
Once the diagnosis of NSTI has been established, initial aggressive debridement of all infected 275 necrotic tissue is indicated (Figures 2 and 3) ; in critically ill patients, a relook within 24 h is 276 recommended to ensure the adequacy of source control [14] . A major amputation is rarely 277 necessary in NSTI, except for patients suffering from clostridial myonecrosis [52] . Clinical diversity may be huge in NSTI, but sepsis and septic shock are frequent. It is therefore 313 particularly important to initiate broad-spectrum, bactericidal antimicrobial therapy without any 314 delay upon diagnosis [14, 15] . Given the severity of illness and the lack of criteria that allow to 315 discriminate mixed and GAS infection rapidly, a broad-spectrum antibiotic regimen should be 316 selected, such as piperacillin-tazobactam, a carbapenem or a 3 rd generation cephalosporin 317 combined with metronidazole, always with the addition of clindamycin to limit potential toxin 318 production. Combination therapy using clindamycin is also recommended in the directed antibiotic 319 therapy for monomicrobial gram-positive infection with GAS or Clostridium species [15] . Depending 320 on local epidemiology, extended coverage for MDR pathogens may be required. toxin production [103] , an effect that was also demonstrated in an in vivo GAS NSTI murine model 327 and proposed to contribute to less severe tissue pathology noted in clindamycin treated mice [104] . 328
In two prospective observational studies of invasive GAS infections, including STSS and NSTI cases, 329
clindamycin was found to be associated with a significantly improved survival [104] [105] [106] . Treatment 330 options in less frequent aetiologies of monomicrobial NSTI are presented in Table 3 . 331 332 Duration of therapy is not well defined, but typically it is continued until operative debridement has 333 been completed and the patient is recovering, usually lasting around 7-10 days in total. 334 M A N U S C R I P T What is the effect of HBOT?
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Is combination therapy with clindamycin superior to monotherapy?
Is aggressive surgery superior to conservative surgery?
What is the appropriate duration of antibiotic therapy?
Is there a benefit of negative pressure therapy?
Organizational Do we need to centralize care for patients with NSTI?
Outcomes What is the health-related quality of life after NSTI?
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The pathophysiology of NSTI is incompletely understood, e.g., the role of the innate immune 376 response to locally control these infections or on the other hand, mediate tissue pathology. Basic 377 research in this field may help to find new targets for diagnostics and intervention, as well as 378 provide critical insight to support patient stratification and personalized medicine in NSTI; GAS is an 379 important pathogen and deserves particular attention. 
SUSPICION OF NSTI Obtain microbiological samples (blood and skin cultures)
Initiate broad-spectrum antibiotic treatment
